A novel subtype classification and risk of breast cancer by histone modification profiling

Breast cancer has been classified into several intrinsic molecular subtypes on the basis of genetic and epigenetic factors. However, knowledge about histone modifications that contribute to the classification and development of biologically distinct breast cancer subtypes remains limited. Here we compared the genome-wide binding patterns of H3K4me3 and H3K27me3 between human mammary epithelial cells and three breast cancer cell lines representing the luminal, HER2, and basal subtypes. We characterized thousands of unique binding events as well as bivalent chromatin signatures unique to each cancer subtype, which were involved in different epigenetic regulation programs and signaling pathways in breast cancer progression. Genes linked to the unique histone mark features exhibited subtype-specific expression patterns, both in cancer cell lines and primary tumors, some of which were confirmed by qPCR in our primary cancer samples. Finally, histone mark-based gene classifiers were significantly correlated with relapse-free survival outcomes in patients. In summary, we have provided a valuable resource for the identification of novel biomarkers of subtype classification and clinical prognosis evaluation in breast cancers.

[1]  A. Nobel,et al.  Supervised risk predictor of breast cancer based on intrinsic subtypes. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  Z. Zhao,et al.  Identification of differentially expressed miRNAs in individual breast cancer patient and application in personalized medicine , 2016, Oncogenesis.

[3]  Matthew D. Wilkerson,et al.  ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking , 2010, Bioinform..

[4]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[5]  Brian A. Kennedy,et al.  Multivalent epigenetic marks confer microenvironment-responsive epigenetic plasticity to ovarian cancer cells , 2010, Epigenetics.

[6]  Yudong D. He,et al.  Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.

[7]  C. Glass,et al.  Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. , 2010, Molecular cell.

[8]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumours , 2013 .

[9]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[10]  Cory Y. McLean,et al.  GREAT improves functional interpretation of cis-regulatory regions , 2010, Nature Biotechnology.

[11]  Danny Reinberg,et al.  A double take on bivalent promoters. , 2013, Genes & development.

[12]  Helga Thorvaldsdóttir,et al.  Integrative Genomics Viewer , 2011, Nature Biotechnology.

[13]  L. Vives,et al.  Bivalent domains enforce transcriptional memory of DNA methylated genes in cancer cells , 2008, Proceedings of the National Academy of Sciences.

[14]  S. Cole,et al.  Intrinsic Breast Tumor Subtypes, Race, and Long-Term Survival in the Carolina Breast Cancer Study , 2010, Clinical Cancer Research.

[15]  Cole Trapnell,et al.  Ultrafast and memory-efficient alignment of short DNA sequences to the human genome , 2009, Genome Biology.

[16]  C. Perou,et al.  Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. , 2006, JAMA.

[17]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[18]  James A. Cuff,et al.  A Bivalent Chromatin Structure Marks Key Developmental Genes in Embryonic Stem Cells , 2006, Cell.

[19]  K. Hess,et al.  DNA mismatch repair gene polymorphisms affect survival in pancreatic cancer. , 2011, The oncologist.

[20]  Aaron R. Quinlan,et al.  Bioinformatics Applications Note Genome Analysis Bedtools: a Flexible Suite of Utilities for Comparing Genomic Features , 2022 .

[21]  Jacob C. Ulirsch,et al.  Vimentin DNA methylation predicts survival in breast cancer , 2012, Breast Cancer Research and Treatment.

[22]  Charles M Perou,et al.  Molecular stratification of triple-negative breast cancers. , 2010, The oncologist.

[23]  G. Yousef,et al.  Prognostic significance of metastasis-related microRNAs in early breast cancer patients with a long follow-up. , 2014, Clinical chemistry.

[24]  J. Weinstein,et al.  Comprehensive analysis of long non-coding RNAs in human breast cancer clinical subtypes , 2014, Oncotarget.

[25]  Henry W. Long,et al.  Somatic Cell Fusions Reveal Extensive Heterogeneity in Basal-like Breast Cancer. , 2015, Cell reports.

[26]  Colleen D. McCabe,et al.  Genome-wide promoter analysis of the SOX4 transcriptional network in prostate cancer cells. , 2009, Cancer research.

[27]  Jenny G. Parvani,et al.  Sox4, EMT programs, and the metastatic progression of breast cancers: mastering the masters of EMT , 2013, Breast Cancer Research.

[28]  Wayne A. Phillips,et al.  Mutation of the PIK3CA Gene in Ovarian and Breast Cancer , 2004, Cancer Research.

[29]  W. Ritchie,et al.  ASCT2/SLC1A5 controls glutamine uptake and tumour growth in triple-negative basal-like breast cancer , 2015, Oncogene.

[30]  Anushya Muruganujan,et al.  Large-scale gene function analysis with the PANTHER classification system , 2013, Nature Protocols.

[31]  Ajay N. Jain,et al.  Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. , 2006, Cancer cell.

[32]  Paul Theodor Pyl,et al.  HTSeq—a Python framework to work with high-throughput sequencing data , 2014, bioRxiv.

[33]  Mohamed-Ashick M. Saleem,et al.  The inactive X chromosome is epigenetically unstable and transcriptionally labile in breast cancer , 2015, Genome research.

[34]  Benjamin Haibe-Kains,et al.  DNA methylation profiling reveals a predominant immune component in breast cancers , 2011, EMBO molecular medicine.

[35]  R. Weinberg,et al.  Poised with purpose: Cell plasticity enhances tumorigenicity , 2013, Cell cycle.

[36]  M. Cronin,et al.  A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. , 2004, The New England journal of medicine.

[37]  J. Foekens,et al.  Hallmarks of aromatase inhibitor drug resistance revealed by epigenetic profiling in breast cancer. , 2013, Cancer research.

[38]  Brad T. Sherman,et al.  Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources , 2008, Nature Protocols.

[39]  M. Fraga,et al.  DNA methylation epigenotypes in breast cancer molecular subtypes , 2010, Breast Cancer Research.

[40]  Arnoldo Frigessi,et al.  Genome-wide DNA methylation profiles in progression to in situ and invasive carcinoma of the breast with impact on gene transcription and prognosis , 2014, Genome Biology.

[41]  Lior Pachter,et al.  Sequence Analysis , 2020, Definitions.